Repare Therapeutics Inc. has 5 Schedule 13D or 13G filings on record since 2025-11-21. 1 holder's latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Shay Capital LLC | 6.7% | 2,870,141 | SCHEDULE 13G, 2026-01-27 | 2026-01-20 |
| Versant Venture Capital V, L.P. | 0.2% | 0 | SCHEDULE 13D/A, 2025-11-21 | 2025-11-19 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13D/A, 2026-01-30 | 2026-01-28 |
| Blue Owl Capital Holdings LP | 0% | 0 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
Purpose of Transaction (Item 4)
Biotechnology Value Fund L P
Item 4 is hereby amended to add the following: Effective January 28, 2026, the Issuer was acquired by Xeno Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of XenoTherapeutics, Inc. ("Xeno"), pursuant to an Arrangement Agreement, dated as of November 14, 2025 (the "Agreement"), under the Business Corporations Act (Quebec), by and among the Issuer, Xeno, Purchaser, and solely for limited purposes, XOMA Royalty Corporation, pursuant to which Purchaser agreed to acquire all of the issued and outstanding Shares of the Issuer. Pursuant to the Agreement, among other things, the Purchaser acquired all of the issued and outstanding Shares of the Issuer in exchange for: (i) $2.20 in cash per Share and (ii) one contingent value right per Share for potential cash payments. Accordingly, the Reporting Persons ceased to beneficially own any securities of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-01-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-21 | Versant Venture Capital V, L.P. | 0.2% | SCHEDULE 13D/A |
| 2025-11-24 | Biotechnology Value Fund L P | 24% | SCHEDULE 13D/A |
| 2026-01-27 | Shay Capital LLC | 6.7% | SCHEDULE 13G |
| 2026-01-30 | Biotechnology Value Fund L P | 0% | SCHEDULE 13D/A |
| 2026-05-14 | Blue Owl Capital Holdings LP | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Repare Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.